The presence of hypoxia is a general feature of most solid malignancies, and hypoxia is considered as one of major factors for anticancer therapy failure. Carbonic anhydrase IX (CAIX) has been reported to be an endogenous hypoxia marker, CAIX monoclonal antibodies, their segments and inhibitors are developed for CAIX imaging. However, growing evidence indicates that CAIX expression under hypoxia condition may be cancer cell lines or cancer-type dependent. Here we review the current literature on CAIX and discuss the advantage and limitation of CAIX as a target for tumor hypoxia imaging. Accordingly, CAIX would be unreliable as a universal target for cancer and tumor hypoxia visualization.
KEYWORDS• cancer • carbonic anhydrase IX • hypoxia • molecular imagingIn 2013, approximately 1,660,290 new cancer cases are diagnosed and 580,350 patients are died of cancer in the USA [1]. Hypoxia is a common feature of large primary solid malignancies and is recognized as a negative determinant of clinical outcome [2][3][4][5][6][7][8][9]. It is now established that tumor hypoxia is an important determinant of relapse-free survival and overall clinical outcome [4,[10][11]]. This appears to be largely independent of the treatment modality used and implies that hypoxia is associated with a more aggressive tumor phenotype. There seems to be at least three distinct manifestations of the hypoxic phenotype: Hypoxic cells are more resistant to ionizing radiation and chemotherapy than aerobic cells; The hypoxic environment is selective for genetically unstable tumor cells, and hypoxia is associated with tumors that are more likely to metastasize [10,12-13]; and hypoxia regulates the level of HIF-1α, which controls the expression of genes that are involved in oxygen and glucose supply and utilization [14]. Therefore, it is important to detect the hypoxic status for solid cancers.Recently multiple biomarkers related to tumor hypoxic microenvironment have been discovered and offered as targets for cancer detection, treatment and monitoring, such as HIF-1 [15][16][17], VEGF and VEGF receptors [18][19][20], glucose transporter 1 [21][22][23] and carbonic anhydrase IX (CAIX) [24][25][26][27][28][29]. CAIX is strongly induced by hypoxia through the HIF-1 transcription factor, and has reported to overexpress in some types of cancer [30,31]. Promising results for using anti-CAIX antibodies and CAIX inhibitors for tumor hypoxia imaging have been reported [32][33][34].However, growing evidence indicates that the CAIX expression under hypoxia conditions in cancer cell lines is cancer cell lines or cancer types dependent [30], and some cancer cell lines have undetectable CAIX expression under hypoxia condition [35,36]. In addition, re-oxygenated (previously hypoxic) cancer cells may still show high level of CAIX expression [36]; CAIX has a half-life up to 2-3 days under normoxic condition. In contrast, acute hypoxic cancer cells may not express detectable CAIX. The open question is whether CAIX is a reliable and universal target for canc...